NCT05387382 is a clinical trial in Bariatric Surgery Candidate, sponsored by The Third Xiangya Hospital of Central South University.

Who is sponsoring NCT05387382?

NCT05387382 is sponsored by The Third Xiangya Hospital of Central South University.

What condition does NCT05387382 study?

NCT05387382 studies Bariatric Surgery Candidate, Adiposity, Fat Redistribution.

Is NCT05387382 still recruiting?

NCT05387382 is currently completed. Last updated 21 September 2023.

Last reviewed 2023-09-21 · How we verify

NCT05387382

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Bariatric Surgery on Different Compositions of Trunk Fat and Mechanisms

Completed Last updated 21 September 2023

What this trial tests

trial in Bariatric Surgery Candidate in 78 participants. Completed in 20 January 2023.

Timeline

20 May 2022

Primary endpoint
20 January 2023

20 January 2023

Quick facts

Lead sponsor	The Third Xiangya Hospital of Central South University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	78
Start date	20 May 2022
Primary completion	20 January 2023
Estimated completion	20 January 2023
Sites	1 location across China

Conditions studied

Bariatric Surgery Candidate — all drugs for Bariatric Surgery Candidate →
Adiposity — all drugs for Adiposity →
Fat Redistribution — all drugs for Fat Redistribution →

Sponsor

The Third Xiangya Hospital of Central South University

Who can join

Adults 18 to 65, any sex, with Bariatric Surgery Candidate or Adiposity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-center, observational study to explore effects of bariatric surgery on different compositions of trunk fat and mechanisms.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of laparoscopic sleeve gastrectomy on mobilization of site-specific body adipose depots: a prospective cohort study.
Cui B, Duan J, Zhu L, Wang G, et al · · 2023 · cited 5× · PMID 37352520 · DOI 10.1097/js9.0000000000000573

Verify or expand the search:

Other recruiting trials for Bariatric Surgery Candidate

Currently open trials in the same condition.

NCT07525232 — Stepwise PEEP vs Sustained Inflation in Bariatric Surgery Patients · NA · recruiting
NCT06511310 — Exercise, Brain Activity, and Weight Maintenance · NA · recruiting
NCT05966727 — Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients · NA · recruiting
NCT06915558 — Modulation of the Inflammatory Response in Bariatric Surgery · recruiting
NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting

Other The Third Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07353307 — A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia Afte · Phase 3 · recruiting
NCT07123207 — Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Dis · NA · recruiting
NCT07034664 — IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study · recruiting
NCT07093294 — Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter · recruiting
NCT07039097 — A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resectio · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05387382 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Third Xiangya Hospital of Central South University
Last refreshed: 21 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05387382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing